Synergia Medical

Global Spotlight for the AURORA Study! Yesterday, we proudly announced that our AURORA study has reached its primary safety endpoint, marking a major step forward in the clinical evaluation of our NAO.VNS™ device for drug-resistant epilepsy (DRE). Meanwhile, across the globe in Kobe, Japan, our investigators Riem El Tahry and Herbert Rooijakkers from Cliniques Universitaires Saint-Luc took the stage at the 6th International Brain Stimulation Conference to present these exciting findings. They were joined by our long-standing advisor, Robert Levy, to share insights on the impact of our pioneering approach to neuromodulation. A huge thank you to them for representing our NAO.VNS™ solution at this prestigious event and for their invaluable contributions to shaping the future of epilepsy treatment!

𝗪𝗲 𝗮𝗿𝗲 𝗽𝗿𝗼𝘂𝗱 𝘁𝗼 𝘀𝗵𝗮𝗿𝗲 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗔𝗨𝗥𝗢𝗥𝗔 𝘀𝘁𝘂𝗱𝘆, 𝘄𝗵𝗶𝗰𝗵 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗲𝘀 𝗼𝘂𝗿 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗡𝗔𝗢.𝗩𝗡𝗦™ 𝗱𝗲𝘃𝗶𝗰𝗲 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗹𝗶𝘃𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗱𝗿𝘂𝗴-𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝘁 𝗲𝗽𝗶𝗹𝗲𝗽𝘀𝘆 (𝗗𝗥𝗘). In partnership with UZ Gent and Cliniques universitaires Saint-Luc in Belgium, the device has been successfully implanted in five patients, marking a significant milestone in neuromodulation therapy. The key results we’ve found three months post-implantation: 💡𝗦𝗮𝗳𝗲𝘁𝘆 𝗙𝗶𝗿𝘀𝘁: The primary safety endpoint was met with no serious adverse events. Minor side effects, including mild coughing and skin numbness, align with existing VNS treatments. 💡𝗦𝗲𝗮𝗺𝗹𝗲𝘀𝘀 𝗜𝗺𝗽𝗹𝗮𝗻𝘁𝗮𝘁𝗶𝗼𝗻: 100% success rate in device implantation and therapy delivery, with no device failures reported. 💡𝗘𝗻𝗰𝗼𝘂𝗿𝗮𝗴𝗶𝗻𝗴 𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆: A 40% responder rate (≥50% seizure reduction) was observed at three months, consistent with current VNS therapy benchmarks. Notably, one patient is seizure free at six months. 💡𝗜𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗼𝗳 𝗟𝗶𝗳𝗲: Patients have reported not only fewer seizures but also reduced severity, improved mood, and decreased depressive symptoms. 💡𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗘𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲: Our rapid recharge technology enables just one minute of daily charging or seven minutes per week, making therapy more convenient and patient-friendly. These results have already drawn media attention, with coverage in La Libre highlighting the breakthrough nature of this study: https://shorturl.at/dLaX2) We’ll build on these promising first-in-human results by preparing for pivotal FDA and CE trials. Our goal is to deliver this life-changing technology to patients worldwide, addressing the needs of the estimated one million people living with DRE in the US alone. DRE is a condition associated with high healthcare costs and significant quality-of-life challenges. We are grateful to our clinical partners, patients, and their families for their trust and collaboration in this journey. We are taking a decisive step toward reshaping epilepsy treatment and improving patient outcomes. A special thank you to the neurologists and neurosurgeons of this study: Kristl Vonck Riem El Tahry Herbert Rooijakkers MD Frank Dewaele 🔗 Learn more: www.synergia-medical.com

𝗛𝗼𝗻𝗼𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝘁𝗿𝘂𝗲 𝗵𝗲𝗿𝗼𝗲𝘀 𝗼𝗳 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗘𝗽𝗶𝗹𝗲𝗽𝘀𝘆 𝗗𝗮𝘆 Epilepsy is not just about seizures. It is a daily struggle, often unseen yet profoundly life-changing. For the millions affected, particularly those with drug-resistant epilepsy (DRE), the impact goes far beyond medical challenges. It disrupts daily life, restricts opportunities, and demands extraordinary resilience. Today, we recognise the true heroes of scientific progress: the patients who put their trust in research. Those who choose to take part in clinical trials do so not only for themselves but also to create a better future for others. At Synergia Medical, conducting our first-in-human study with our optoelectronic Vagus Nerve Stimulation for DRE has been a humbling experience. Every participant is a pioneer, shaping the future of epilepsy treatment. Their trust is an enormous responsibility, one we carry with deep gratitude and unwavering commitment. To everyone living with epilepsy, to the families and caregivers who continue to fight for progress – we see you, we stand with you, and we will not stop striving for better solutions. 𝗧𝗼 𝗼𝘂𝗿 𝗿𝗲𝗺𝗮𝗿𝗸𝗮𝗯𝗹𝗲 𝘀𝘁𝘂𝗱𝘆 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀, 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝗳𝗼𝗿 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝘄𝗮𝘆.

The second act of leadership. I read an exceptionally interesting post (https://lnkd.in/efxd5HkN) recently by Lindsay Hartland, discussing how most founders lead MedTech start-ups. Visionary engineers or scientists who create transformative technologies. But the reality is that many struggle to turn breakthrough technology into clinical and commercial success. Transitioning from innovation to market success requires a distinct set of skills, and recognising this often demands humility and tough decisions. I’ve recently stepped into the role of CEO at a critical juncture for our company. It’s a privilege to build on the incredible foundation laid by the founding team, and I’m acutely aware of the responsibility that comes with this transition. Advancing our neuromodulation innovation from clinical to commercialization won’t just require a sound strategy or scaling; it’ll require collaboration, trust, and ensuring the innovation reaches patients who need it. Leadership isn’t about one person. It’s about a team working together to create a real impact. In start-ups, we must constantly ask hard questions about leadership to keep the mission front and centre in everything we do. Ultimately, it’s not about who leads but about the lives we aim to improve. Thank you to all of these people for all of the incredible work. Stéphanie Cortembos Isabelle Deroubaix Dimitri Crelot Dan Scherrer Carmen Godfraind Yohan Botquin Aurore Nieuwenhuys Grégory Thiebaut Gijs Klarenbeek Marine Bion Sébastien Berlemont Vincent De Rudder Anne Renaud Jérôme Garnier Le Pallec Catherine Léonard Augustin Jadoul Pauline Carreras Francois Dachelet Patrice Bastiaens Axel Boland Mohamed Lanjri Renske Dezwaef

🌟 Shining Bright in 2024, lighting the Way for 2025 🌟    🎉 2024 Breakthrough Achievement:  At Synergia Medical, 2024 marked a pivotal moment in our mission to revolutionize neurostimulation : Successfully implanting five patients with our innovative NAO.VNSTM system as part of the AURORA study.  This milestone reflects the dedication of our team, the expertise of our clinical partners, and the visionary leadership of Attila Borbáth, our co-founder and outgoing CEO.    🚀 Looking Ahead to 2025:  As we step into this exciting new chapter, we remain laser-focused on providing life-changing solutions for patients with drug-resistant epilepsy and redefining what’s possible in neurostimulation.    🌟 Our Key Goals for 2025:  - 🚀 Advancing pivotal clinical studies,  - 🤝 Strengthening global collaborations with medical innovators, and  - 🌍Scaling production to bring our groundbreaking solution closer to commercialization.    👨💼 Welcoming New Leadership:  We are thrilled to welcome Charles Nolet as our new CEO! With his extensive MedTech expertise, Charles is ready to lead Synergia into this next phase of innovation and growth.    Let’s make 2025 a year of collaboration, impact, and progress. Together, we can light the way forward and transform lives!    🙏 To our team, partners, and stakeholders: thank you for your continued support    #Innovation #EpilepsyCare #Neurostimulation #MedTech #SynergiaMedical

We are thrilled to announce the success of our first 2 patient implantations with our #NAO.VNS device. Implanted on September 6th, both patients have started stimulation therapy and follow-up visits at the end of last week.   It has been a great honour to work with the enthusiastic and expert teams in the two leading epilepsy centers in #Belgium. Cliniques universitaires Saint-Luc  UZ Gent   Many thanks to them for their support and we look forward to pursuing our clinical trials together! Herbert Rooijakkers MD  Frank Dewaele Kristl Vonck Riëm El Tahry Attila Borbáth Anne Renaud Catherine Léonard Dan Scherrer Gijs Klarenbeek Vincent De Rudder Aurore Nieuwenhuys Pascal Doguet Sophie Baratte, MBA, PhD James Palmer #NAO.VNS #epilepsy #DRE #optoelectronics #drugresistantepilepsy #medtech  

Our whole team at Synergia Medical is greatly honored to have been nominated for the prestigious #2024 International Prix Galien. Thanks to the The Galien Foundation for bringing recognition of our breakthrough epilepsy treatment to the international stage.   #Naovns #FIH trials to start soon…watch this space! Attila Borbáth Anne Renaud Sophie Baratte, MBA, PhD Catherine Léonard Aurore Nieuwenhuys Vincent De Rudder Dan Scherrer Gijs Klarenbeek #drugresistantepilepsy #epilepsy #optoelctronics #naovns

Fantastic achievement, thank you all for your dedication!

Fantastic achievement, thank you all for your dedication!

IMPORTANT #ABSTRACT by Synergia Medical in Nature Portfolio We are delighted to announce the publication of a significant article/abstract in the world renown Nature Portfolio magazine today. The article in the Scientific Report section focuses on the benefits of Synergia Medical’s NAO.VNS. The open communication is entitled “An optoelectronic implantable neurostimulation platform allowing full MRI safety and optical sensing and communication” and concludes that “the NAO∙VNS is the first-of-its-kind implantable neurostimulator using an optoelectronic approach.” The whole team at Synergia Medical is immensely proud to have had the white paper accepted. The NAO.VNS therapy brings great hope to drug resistant epilepsy sufferers – both adults & children – First in Human clinical trials are set to start soon…. Read more about "An optoelectronic implantable neurostimulation platform allowing full MRI safety and optical sensing and communication" https://lnkd.in/ewGNPi9K Pascal Doguet, Jérôme Garnier Le Pallec, Aurore Nieuwenhuys, Carmen Godfraind, Yohan Botquin , John Justice, Antoine Nonclercq, Riëm El Tahry, Brian Corbett  Jean Delbeke Scientific Reports volume  14, Article number: 11110 (2024)